Literature DB >> 32016057

Immune-checkpoint inhibitors and the importance of concomitant medications: focus on antibiotics.

Chiara Casadei1, Cristian Lolli1, Alberto Farolfi1.   

Abstract

Year:  2019        PMID： 32016057      PMCID： PMC6976445          DOI： 10.21037/atm.2019.09.99

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

1.  Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.

Authors:  Ugo De Giorgi; Giuseppe Procopio; Diana Giannarelli; Roberto Sabbatini; Alessandra Bearz; Sebastiano Buti; Umberto Basso; Manfred Mitterer; Cinzia Ortega; Paolo Bidoli; Francesco Ferraù; Lucio Crinò; Antonio Frassoldati; Paolo Marchetti; Enrico Mini; Alessandro Scoppola; Claudio Verusio; Giuseppe Fornarini; Giacomo Cartenì; Claudia Caserta; Cora N Sternberg
Journal:  Clin Cancer Res       Date:  2019-04-09       Impact factor: 12.531

2.  Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

Authors:  Ugo De Giorgi; Giacomo Cartenì; Diana Giannarelli; Umberto Basso; Luca Galli; Enrico Cortesi; Claudia Caserta; Sandro Pignata; Roberto Sabbatini; Alessandra Bearz; Sebastiano Buti; Giovanni Lo Re; Alfredo Berruti; Sergio Bracarda; Francesco Cognetti; Francesca Rastelli; Giuseppe Fornarini; Camillo Porta; Daniele Turci; Cora N Sternberg; Giuseppe Procopio
Journal:  BJU Int       Date:  2018-07-23       Impact factor: 5.588

Review 3.  Cutaneous side-effects of kinase inhibitors and blocking antibodies.

Authors:  Caroline Robert; Jean-Charles Soria; Alain Spatz; Axel Le Cesne; David Malka; Patricia Pautier; Janine Wechsler; Catherine Lhomme; Bernard Escudier; Valérie Boige; Jean-Pierre Armand; Thierry Le Chevalier
Journal:  Lancet Oncol       Date:  2005-07       Impact factor: 41.316

4.  Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.

Authors:  Nadina Tinsley; Cong Zhou; Grace Tan; Samuel Rack; Paul Lorigan; Fiona Blackhall; Matthew Krebs; Louise Carter; Fiona Thistlethwaite; Donna Graham; Natalie Cook
Journal:  Oncologist       Date:  2019-07-10

Review 5.  Immunomodulatory effects of quinolones.

Authors:  Axel Dalhoff; Itamar Shalit
Journal:  Lancet Infect Dis       Date:  2003-06       Impact factor: 25.071

6.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.

Authors:  L Derosa; M D Hellmann; M Spaziano; D Halpenny; M Fidelle; H Rizvi; N Long; A J Plodkowski; K C Arbour; J E Chaft; J A Rouche; L Zitvogel; G Zalcman; L Albiges; B Escudier; B Routy
Journal:  Ann Oncol       Date:  2018-06-01       Impact factor: 32.976

Review 7.  Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators.

Authors:  Evangelos J Giamarellos-Bourboulis
Journal:  Int J Antimicrob Agents       Date:  2007-11-01       Impact factor: 5.283

8.  Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

Authors:  Cristian Lolli; Orazio Caffo; Emanuela Scarpi; Michele Aieta; Vincenza Conteduca; Francesca Maines; Emanuela Bianchi; Francesco Massari; Antonello Veccia; Vincenzo E Chiuri; Gaetano Facchini; Ugo De Giorgi
Journal:  Front Pharmacol       Date:  2016-10-13       Impact factor: 5.810

9.  Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.

Authors:  Cristian Lolli; Umberto Basso; Lisa Derosa; Emanuela Scarpi; Teodoro Sava; Matteo Santoni; Simon J Crabb; Francesco Massari; Michele Aieta; Vincenza Conteduca; Marco Maruzzo; Francesca La Russa; Matthew Wheater; Rossana Berardi; Luca Galli; Ugo De Giorgi
Journal:  Oncotarget       Date:  2016-08-23

Review 10.  The Impact of the Adipose Organ Plasticity on Inflammation and Cancer Progression.

Authors:  Luís Henrique Corrêa; Gabriella Simões Heyn; Kelly Grace Magalhaes
Journal:  Cells       Date:  2019-06-30       Impact factor: 6.600
View more
  1 in total

1.  Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.

Authors:  N Tinsley; C Zhou; S Nahm; S Rack; G C L Tan; P Lorigan; F Blackhall; N Cook
Journal:  ESMO Open       Date:  2022-04-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.